[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:f8-wt-allele":3},{"name":4,"total":5,"recruiting":5,"trials":6},"F8 wt Allele",10,[7,15,22,28,35,41,47,53,59,65],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07220564","A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A",[11],"Phase 1","RECRUITING","2026-08-26T02:16:35.654046Z","2026-05-05T02:43:29.541199Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04563520","SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis",[19],"Phase 3","2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.467183Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06703606","A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.",[11],"2026-08-26T02:15:14.574786Z","2026-05-05T02:43:28.487834Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT06941870","Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy",[32],"Phase 4","2026-08-26T02:17:52.450442Z","2026-05-05T02:43:28.469973Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT05936580","Nuwiq Dosing and Outcomes In the ManagEment of Women\u002FGirls With Haemophilia A Needing FVIII Treatment for Surgery",[32],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:28.191088Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":45,"content_modified":46},"NCT07285460","A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B",[19],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:27.842950Z",{"nct_id":48,"title":49,"phases":50,"status":12,"updated_at":39,"content_modified":52},"NCT05987449","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A",[51],"Phase 1\u002FPhase 2","2026-05-05T02:43:26.727335Z",{"nct_id":54,"title":55,"phases":56,"status":12,"updated_at":57,"content_modified":58},"NCT06349473","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)",[11],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:27.336527Z",{"nct_id":60,"title":61,"phases":62,"status":12,"updated_at":63,"content_modified":64},"NCT07414511","Hemophilia A Research Program",[],"2026-08-26T02:15:51.395565Z","2026-05-13T02:55:06.701372Z",{"nct_id":66,"title":67,"phases":68,"status":12,"updated_at":69,"content_modified":70},"NCT05022459","Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis",[],"2026-08-26T02:16:02.918558Z","2026-05-13T02:55:06.278798Z"]